NASDAQ:LUNG - Pulmonx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.00
  • Forecasted Upside: 41.63 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$39.54
▼ -0.11 (-0.28%)

This chart shows the closing price for LUNG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pulmonx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LUNG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUNG

Analyst Price Target is $56.00
▲ +41.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Pulmonx in the last 3 months. The average price target is $56.00, with a high forecast of $72.00 and a low forecast of $50.00. The average price target represents a 41.63% upside from the last price of $39.54.

This chart shows the closing price for LUNG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Pulmonx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2021Canaccord GenuityLower Price TargetBuy$65.00 ➝ $53.00High
4/1/2021CitigroupInitiated CoverageBuy$60.00Low
3/25/2021Piper SandlerInitiated CoverageNeutral$50.00High
3/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$72.00High
3/3/2021Wells Fargo & CompanyBoost Price Target$46.00 ➝ $54.00Medium
3/3/2021Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $53.00High
3/3/2021Canaccord GenuityBoost Price TargetBuy$49.00 ➝ $65.00High
1/4/2021Bank of AmericaDowngradeBuy ➝ NeutralN/A
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$46.00 ➝ $52.00Medium
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$44.00 ➝ $46.00High
10/26/2020Bank of AmericaInitiated CoverageBuy$50.00Medium
10/26/2020Morgan StanleyInitiated CoverageEqual Weight$44.00Low
10/26/2020Stifel NicolausInitiated CoverageBuy$50.00Low
10/26/2020Canaccord GenuityInitiated CoverageBuy$49.00Low
10/26/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$46.00Low
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/24/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Pulmonx logo
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $39.54
Low: $39.07
High: $39.90

50 Day Range

MA: $38.69
Low: $35.98
High: $42.29

52 Week Range

Now: $39.54
Low: $35.81
High: $69.48

Volume

201,005 shs

Average Volume

343,535 shs

Market Capitalization

$1.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulmonx?

The following Wall Street analysts have issued research reports on Pulmonx in the last year: Bank of America Co., Canaccord Genuity, Citigroup Inc., Morgan Stanley, Piper Sandler, Stifel Nicolaus, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for LUNG.

What is the current price target for Pulmonx?

7 Wall Street analysts have set twelve-month price targets for Pulmonx in the last year. Their average twelve-month price target is $56.00, suggesting a possible upside of 41.6%. Bank of America Co. has the highest price target set, predicting LUNG will reach $72.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $50.00 for Pulmonx in the next year.
View the latest price targets for LUNG.

What is the current consensus analyst rating for Pulmonx?

Pulmonx currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LUNG will outperform the market and that investors should add to their positions of Pulmonx.
View the latest ratings for LUNG.

How do I contact Pulmonx's investor relations team?

The company's listed phone number is 650-364-0400 and its investor relations email address is [email protected] The official website for Pulmonx is pulmonx.com.